The efficacy and safety of heparin in patients with sepsis: A systematic review and metaanalysis

Critical Care Medicine

Volumn 43, Issue 3, 2015, Pages 511-518

  Zarychanski, Ryan ^a,b,c   Abou Setta, Ahmed M ^c   Kanji, Salmaan ^d   Turgeon, Alexis F ^e   Kumar, Anand ^a   Houston, Donald S ^b   Rimmer, Emily ^b   Houston, Brett L ^f   McIntyre, Lauralyn ^d   Fox Robichaud, Alison E ^g   Hébert, Paul ^g   Cook, Deborah J ^g   Fergusson, Dean A ^d  

^a UNIVERSITY OF MANITOBA   (Canada)

^b CANCERCARE MANITOBA   (Canada)

^c WINNIPEG REGIONAL HEALTH AUTHORITY   (Canada)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^e Université Laval   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g MCMASTER UNIVERSITY   (Canada)

Author keywords

Disseminated intravascular coagulation; Heparin; Metaanalysis; Mortality; Sepsis; Systematic review

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; ANTICOAGULANT AGENT;

BLEEDING; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EMBASE; ERYTHROCYTE TRANSFUSION; FOLLOW UP; HUMAN; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCOPUS; SEPSIS; SEPTIC SHOCK; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; WEB OF SCIENCE; BLOOD TRANSFUSION; CHEMICALLY INDUCED; DISSEMINATED INTRAVASCULAR COAGULATION; MORTALITY; SHOCK, SEPTIC; STATISTICS AND NUMERICAL DATA;

ANTICOAGULANTS; BLOOD TRANSFUSION; DISSEMINATED INTRAVASCULAR COAGULATION; HEMORRHAGE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEPSIS; SHOCK, SEPTIC; THROMBOCYTOPENIA;

EID: 84924230426     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000000763     Document Type: Review

References (51)

1. Angus DC, van der Poll T: Severe sepsis and septic shock. N Engl J Med 2013; 369:840-851
2. Martin GS, Mannino DM, Eaton S, et al: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-1554
3. Bernard GR, Vincent JL, Laterre PF, et al; Recombinant Human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
4. Dellinger RP: Cardiovascular management of septic shock. Crit Care Med 2003; 31:946-955
5. Warren BL, Eid A, Singer P, et al; KyberSept Trial Study Group: Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: A randomized controlled trial. JAMA 2001; 286:1869-1878
6. Aird WC: The hematologic system as a marker of organ dysfunction in sepsis. Mayo Clin Proc 2003; 78:869-881
7. Levi M, Schultz M, van der Poll T: Coagulation biomarkers in critically ill patients. Crit Care Clin 2011; 27:281-297
8. Abraham E, Reinhart K, Opal S, et al; OPTIMIST Trial Study Group: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA 2003; 290:238-247
9. Li JP, Vlodavsky I: Heparin, heparan sulfate and heparanase in inflammatory reactions. Thromb Haemost 2009; 102:823-828
10. Ludwig RJ: Therapeutic use of heparin beyond anticoagulation. Curr Drug Discov Technol 2009; 6:281-289
11. Anastase-Ravion S, Blondin C, Cholley B, et al: Heparin inhibits lipopolysaccharide (LPS) binding to leukocytes and LPS-induced cytokine production. J Biomed Mater Res A 2003; 66:376-384
12. Lantz M, Thysell H, Nilsson E, et al: On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin. J Clin Invest 1991; 88:2026-2031
13. Lever R, Hoult JR, Page CP: The effects of heparin and related molecules upon the adhesion of human polymorphonuclear leucocytes to vascular endothelium in vitro. Br J Pharmacol 2000; 129:533-540
14. Smailbegovic A, Lever R, Page CP: The effects of heparin on the adhesion of human peripheral blood mononuclear cells to human stimulated umbilical vein endothelial cells. Br J Pharmacol 2001; 134:827-836
15. Cornet AD, Smit EG, Beishuizen A, et al: The role of heparin and allied compounds in the treatment of sepsis. Thromb Haemost 2007; 98:579-586
16. Filkins JP, Di Luzio NR: Heparin protection in endotoxin shock. Am J Physiol 1968; 214:1074-1077
17. Griffin MP, Gore DC, Zwischenberger JB, et al: Does heparin improve survival in experimental porcine gram-negative septic shock? Circ Shock 1990; 31:343-349
18. Zarychanski R, Doucette S, Fergusson D, et al: Early intravenous unfractionated heparin and mortality in septic shock. Crit Care Med 2008; 36:2973-2979
19. Polderman KH, Girbes AR: Drug intervention trials in sepsis: Divergent results. Lancet 2004; 363:1721-1723
20. Zarychanski R, Abou-Setta AM, Kanji S, et al: The efficacy and safety of heparin in patients with sepsis: A systematic review and metaanalysis. International Prospective Register of Systematic Reviews (PROSPERO). 2013. Available at: http://www.crd.york.ac.uk/PROSPERO/display-record.asp?ID=CRD42013003591. Accessed June 6, 2014
21. Chandler J, Churchill R, Higgins J, et al: Methodological standards for the conduct of new Cochrane Intervention Reviews (Version 2.2). In: Methodological Expectations of Cochrane Intervention Reviews (MECIR), London, UK, The Cochrane Collaboration, 2012
22. Liberati A, Altman DG, Tetzlaff J, et al: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med 2009; 6:e1000100
23. Abou-Setta AM, Klassen T, Kirby S, et al: You can learn a lot from a DUMMY: Improving search strategies using the 'Diagnostic Utility for Mining MEDLINE' (DUMMY). In: Cochrane Database Syst Rev-2012 Cochrane Colloquium, London, UK, The Cochrane Collaboration, 2012, p 21
24. Higgins JPT, Green S: Assessing risk of bias in included studies. In: Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. London, UK, The Cochrane Collaboration, 2011
25. Higgins JPT, Altman DG, Gotzche PC, et al: The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 18; 343:d5928
26. Higgins JP, Thompson SG: Quantifying heterogeneity in a metaanalysis. Stat Med 2002; 21:1539-1558
27. Ioannidis JP, Trikalinos TA: The appropriateness of asymmetry tests for publication bias in meta-analyses: A large survey. CMAJ 2007; 176:1091-1096
28. Guyatt GH, Oxman AD, Vist GE, et al; GRADE Working Group: GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336:924-926
29. Haneberg B, Gutteberg TJ, Moe PJ, et al: Heparin for infants and children with meningococcal septicemia. Results of a randomized therapeutic trial. NIPH Ann 1983; 6:43-47
30. Jaimes F, De La Rosa G, Morales C, et al: Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study). Crit Care Med 2009; 37:1185-1196
31. Levi M, Levy M, Williams MD, et al; Xigris and Prophylactic HepaRin Evaluation in Severe Sepsis (XPRESS) Study Group: Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med 2007; 176:483-490
32. Saito H, Maruyama I, Shimazaki S, et al: Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: Results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007; 5:31-41
33. Ghanem JJ, San Juan J, Enrico E, et al: Sepsis: Estudio comparativo en el tratamiento de las alteraciones de coagulaci¢n con concentrados de Antitrombina III o Heparina. Med Intensiva 1996; 13:91-101
34. Vinazzer H: [Use of antithrombin III concentrates]. Beitr Infusionsther 1989; 24:151-158
35. Zhang XJ, Ma XC: [Therapeutic effects of early administration of low-dose heparin in patients with severe sepsis]. Zhonghua Wai Ke Za Zhi 2006; 44:1209-1211
36. Zhao C, Zhang ZD, Zhang XJ, et al: [Evaluation of clinical effects on low-dose heparin therapy for sepsis]. Zhonghua Nei Ke Za Zhi 2009; 48:566-569
37. Liu XL, Wang XZ, Liu XX, et al: Low-dose heparin as treatment for early disseminated intravascular coagulation during sepsis: A prospective clinical study. Exp Ther Med 2014; 7:604-608
38. Aikawa N, Shimazaki S, Yamamoto Y, et al: Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: Subanalysis from the phase 3 trial. Shock 2011; 35:349-354
39. Levy M, Levi M, Williams MD, et al: Comprehensive safety analysis of concomitant drotrecogin alfa (activated) and prophylactic heparin use in patients with severe sepsis. Intensive Care Med 2009; 35:1196-1203
40. Shorr AF, Williams MD: Venous thromboembolism in critically ill patients. Observations from a randomized trial in sepsis. Thromb Haemost 2009; 101:139-144
41. Ghanem J, San Juan J, Enrico E, et al: Sepsis: A collaborative study on the treatment of coagulation disturbances with antithrombin III or heparin [abstract]. Thromb Haemost 1997; Suppl:517
42. Higgins JPT, Green S: Recommendations on testing for funnel plot asymmetry. In: Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. London, UK, The Cochrane Collaboration, 2011
43. Ranieri VM, Thompson BT, Barie PS, et al; PROWESS-SHOCK Study Group: Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366:2055-2064
44. Zarychanski R: From mice to men: Treating sepsis with heparin. Crit Care Med 2011; 39:1225-1226
45. Lehmann C, Usichenko TI, Pavlovic D: Heparins in sepsis-induced disseminated intravascular coagulation: Low weight-high impact? Crit Care Med 2005; 33:1455-1457
46. Davidson BL, Geerts WH, Lensing AW: Low-dose heparin for severe sepsis. N Engl J Med 2002; 347:1036-1037
47. Almeda S, Rosenberg RD, Bing DH: The binding properties of human complement component C1q. Interaction with mucopolysaccharides. J Biol Chem 1983; 258:785-791
48. Nishimura K, Shima K, Asakura M, et al: Effects of heparin administration on Trypanosoma brucei gambiense infection in rats. J Parasitol 2005; 91:219-222
49. Schultz DR, Becker EL: The alteration of endotoxin by postheparin plasma and purified fractions. II. Relationship of the endotoxin detoxifying activity of euglobulin from postheparin plasma to lipoprotein lipase. J Immunol 1967; 98:482-489
50. Rama-Maceiras P, Ingelmo II, Fàbregas JN, et al: [Fraudulent pain research: A hurt so deep nothing can alleviate it]. Rev Esp Anestesiol Reanim 2009; 56:372-379
51. Editors-in-Chief Statement Regarding Published Clinical Trials Conducted Without IRB Approval by Joachim Boldt. 2011. Available at: http://www.aaeditor.org/EIC.Joint.Statement.on.Retractions.pdf. Accessed October 31, 2012